Home › Lung Cancer › Massachusetts › Worcester
Lung Cancer clinical trials in Worcester, MA
11 studies for Lung Cancer are looking for participants at sites in and around Worcester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecruitingPhase 3
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford · 17 mi away
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RecruitingPhase 3
- Reliant Medical Group Inc, Worcester
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 3
- University of Massachusetts Memorial Medical Center, Worcester
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RecruitingPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- UMass Memorial Medical Center - University Campus, Worcester
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- UMass Memorial Medical Center - University Campus, Worcester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- UMass Memorial Medical Center - University Campus, Worcester
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Worcester
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Arlington, VA41 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Columbus, OH37 studies
- Philadelphia, PA36 studies
Other studies in Worcester
- Non-Small Cell Lung Cancer14 studies
- Cancer (all types)7 studies
- Breast Cancer6 studies
- Schizophrenia5 studies
- Metastatic Cancer5 studies
- Prostate Cancer5 studies
- Ovarian Cancer5 studies
- Major Depressive Disorder5 studies
- Depression5 studies
- Acute Myeloid Leukemia5 studies
- Urothelial (Transitional Cell) Carcinoma4 studies
- Bladder Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.